In vitro and in vivo evaluation of gastroretentive floating drug delivery system of ofloxacin

Asian Journal of Pharmaceutical Sciences

Volumn 8, Issue 3, 2013, Pages 191-198

  Shakya, Rajani ^a   Thapa, Panna ^a   Saha, Ranendra N ^b  

^a KATHMANDU UNIVERSITY   (Nepal)

^b BIRLA INSTITUTE OF TECHNOLOGY AND SCIENCE   (India)

Author keywords

Bioavailability; Box Behnken design; Floating; Gastroretentive drug delivery system; Ofloxacin

Indexed keywords

EID: 84894054755     PISSN: 18180876     EISSN: 2221285X     Source Type: Journal    
DOI: 10.1016/j.ajps.2013.07.025     Document Type: Article

References (32)

1. Moes, A.J., Gastroretentive dosage forms. Crit Rev Ther Drug Carrier Syst 10 (1993), 143–195.
2. Baumgartner, S., Kristl, J., Vrecer, F., Optimization of floating matrix tablets and evaluation of their gastric residence time. Int J Pharm 195 (2000), 125–135.
3. Hoffman, A., Pharmacodynamic aspects of sustained release preparations. Adv Drug Deliv Rev 33 (1998), 185–199.
4. Klausner, E.A., Lavy, E., Friedman, M., et al. Expandable gastroretentive dosage forms. J Control Release 90 (2003), 143–162.
5. Shaha, S.H., Patel, J.K., Pundarikakshudu, K., An overview of a gastroretentive floating drug delivery system. Asian J Pharm Sci 4 (2009), 65–80.
6. Rouge, N., Allemann, E., Gex-Fabry, M., et al. Comparative pharmacokinetic study of a floating multiple-unit capsule, a high-density multiple-unit capsule and an immediate-release tablet containing 25 mg atenolol. Pharm Acta Helv 73 (1998), 81–87.
7. Singh, B.N., Kim, K.H., Floating drug delivery systems: an approach to oral controlled drug delivery via gastric retention. J Control Release 63 (2000), 235–239.
8. Kumar, Jeetendra, Shaik, M.M., Kathi, M.M., et al. Prescribing indicators and pattern of use of antibiotics among medical outpatients in a teaching hospital of central Nepal. J College Med Sci Nepal 6 (2010), 7–13.
9. Chavanpatil, Mahesh, Jain, Paras, Chaudhari, Sachin, et al. Development of sustained release gastroretentive drug delivery system for ofloxacin: in vitro and in vivo evaluation. Int J Pharm 304 (2005), 178–184.
10. Cui, Yue, Zhang, Yu, Tang, Xing, In vitro and in vivo evaluation of ofloxacin sustained release pellets. Int J Pharm 360 (2008), 47–52.
11. Timmermans, J., Moes, A.J., How well floating dosage do forms float?. Int J Pharm 62 (1990), 207–216.
12. Hwang, S.J., Park, H., Park, K., Gastric retentive drug-delivery systems. Crit Rev Ther Drug Carrier Syst 15 (1998), 243–284.
13. Ritger, P.L., Peppas, N.A., A simple equation for description of solute release II. Fickian and anomalous release from swellable devices. J Control Release 5 (1987), 37–42.
14. Talukder, M.M., Michael, A., Rombaut, P., et al. Comparative study on xanthum gum and HPMC as matrices for controlled release drug delivery. Int J Pharm 129 (1996), 231–241.
15. Okeri, Henry A., Arhewoh, Ikhuoria M., Analytical profile of the fluoroquinolone antibacterials. I. Ofloxacin. African J Biotech 7 (2008), 670–680.
16. Gu, T.H., Chen, S.X., Zhu, J.B., Phamacokinetics and pharmacodynamics of diltiazem floating tablets. Yao Xue Xue Bao 13 (1992), 527–531.
17. Ichikawa, M., Watanabe, S., Miyake, S., A new multiple-unit oral floating dosage system. I: preparation and in vitro evaluation of floating and sustained-release characteristics. J Pharm Sci 80 (1991), 1062–1066.
18. Wei, Z., Yu, Z., Bi, D., Design and evaluation of a two-layer floating tablet for gastric retention using cisapride as a model drug. Drug Dev Ind Pharm 27 (2001), 469–474.
19. Gambhire, M.N., Ambade, K.W., Kurmi, S.D., et al. Development and in vitro evaluation of an oral floating matrix tablet formulation of diltiazem hydrochloride. AAPS PharmSciTech, 8(3), 2007 Sep 7, E73.
20. Nagarwal, Ramesh C., Ridhurkar, Devendra N., Pandit, J.K., In vitro release kinetics and bioavailability of gastroretentive cinarizine HCl tablets. AAPS PharmSciTech 1 (2010), 294–302.
21. Jagdale, Swati C., Ghorpade, Swapnil A., Kuchekar, Bhanudas S., et al. Effect of polymer and gas forming agent on floating drug delivery of tramadol hydrochloride using response surface methodology: in vitro and in vivo evaluation. Int J Pharm Appl 2 (2011), 181–194.
22. Tadros, Mina Ibrahim, Controlled release effervescent floating matrix tablets of ciprofloxacin hydrochloride: development, optimization and in vitro evaluation in healthy human volunteers. Eur J Pharm Biopharm 74 (2012), 332–339.
23. Sung, K.C., Nixon, Phillip R., Skoug, John W., et al. Effect of formulation variables on drug and polymer release from HPMC-based matrix tablets. Int J Pharm 142 (1996), 53–60.
24. Siepmann, J., Peppas, N.A., Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose. Adv Drug Deliv Rev 48 (2001), 139–157.
25. Reynolds, T.D., Gehrke, S.H., Hussain, A.S., Polymer erosion and drug release characterization of hydroxypropyl methylcellulose matrices. J Pharm Sci 87 (1998), 1115–1119.
26. Mitchell, K., Ford, J.L., Armstrong, D.J., The influence of drugs on the properties of gels and swelling characteristics of matrices containing methylcellulose or hydroxypropyl methylcellulose. Int J Pharm 100 (1993), 165–173.
27. Mitchell, K., Ford, J.L., Armstrong, D.J., et al. The influence of the particle size of hydroxypropyl methylcellulose K15M on its hydration and performance in matrix tablets. Int J Pharm 100 (1993), 175–179.
28. Siepman, J., Kranz, H., Bodmeir, R., HPMC-Matrices for controlled drug delivery: a new model combining diffusion, swelling, and dissolution mechanisms and predicting the release kinetics. Pharm Res 16 (1999), 1748–1756.
29. Prabhakaran, L., Vishalini, M., Hydrophilic polymers matrix systems of nifedipine sustained release matrix tablets: formulation optimization by response surface method (Box–Behnken technique). Pegalia Res Lib 1 (2010), 147–165.
30. FDA, Guidance on statistical procedures for bioequivalence studies using a standard two-treatment crossover design. 1992, Office of Generic Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Maryland.
31. FDA, Guidance for industry on statistical approaches to establishing bioequivalence. 2001, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Maryland.
32. Marier, J.F., Ducharme, M.P., DiMarco, M., et al. Two open-label, randomized crossover studies assessing the bioequivalence of ofloxacin administered as immediate and extended release formulations in healthy subjects. Clin Ther 28 (2006), 2070–2080.